Basel, 19 August 2015 – Lonza Swiss Finance Ltd, a wholly-owned company of Lonza Group Ltd, Basel (“Lonza”), announces the pricing of its dual tranche CHF 325 million straight bonds. The bonds have a maturity of 5 and 8 years respectively with coupons of 0.625% and 1.250%. The issuer is Lonza Swiss Finance Ltd, Basel, and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the bonds on the SIX Swiss Exchange. The proceeds of the bonds will be used for the refinancing of existing debt.
Key data:
Issue size 5 year bond: CHF 150 million
Expected payment date: 22 September 2015
Maturity: 22 September 2020 (5 years)
Issue price: 100.135 percent
Redemption price: 100 percent
Coupon: 0.625 percent p.a.
Joint Lead Managers: Credit Suisse AG, UBS AG and Zürcher Kantonalbank
Co-Manager: Basler Kantonalbank
Issue size 8 year bond: CHF 175 million
Expected payment date: 22 September 2015
Maturity: 22 September 2023 (8 years)
Issue price: 100.133 percent
Redemption price: 100 percent
Coupon: 1.250 percent p.a.
Joint Lead Managers: Credit Suisse AG, UBS AG and Zürcher Kantonalbank
Co-Manager: Basler Kantonalbank
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
Help employers find you! Check out all the jobs and post your resume.
Key data:
Issue size 5 year bond: CHF 150 million
Expected payment date: 22 September 2015
Maturity: 22 September 2020 (5 years)
Issue price: 100.135 percent
Redemption price: 100 percent
Coupon: 0.625 percent p.a.
Joint Lead Managers: Credit Suisse AG, UBS AG and Zürcher Kantonalbank
Co-Manager: Basler Kantonalbank
Issue size 8 year bond: CHF 175 million
Expected payment date: 22 September 2015
Maturity: 22 September 2023 (8 years)
Issue price: 100.133 percent
Redemption price: 100 percent
Coupon: 1.250 percent p.a.
Joint Lead Managers: Credit Suisse AG, UBS AG and Zürcher Kantonalbank
Co-Manager: Basler Kantonalbank
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
Help employers find you! Check out all the jobs and post your resume.
